682 related articles for article (PubMed ID: 23568992)
21. [Lambert-Eaton myasthenic syndrome: diagnosis and treatment].
Motomura M; Iwanaga H
Clin Calcium; 2001 Nov; 11(11):1468-74. PubMed ID: 15775666
[TBL] [Abstract][Full Text] [Related]
22. [Lambert-Eaton myasthenic syndrome, an immune pathology of neuromuscular junctions].
Honnorat J
Bull Acad Natl Med; 2014 Feb; 198(2):243-54; discussion 255. PubMed ID: 26263702
[TBL] [Abstract][Full Text] [Related]
23. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome.
Fukuda T; Motomura M; Nakao Y; Shiraishi H; Yoshimura T; Iwanaga K; Tsujihata M; Eguchi K
Ann Neurol; 2003 Jan; 53(1):21-8. PubMed ID: 12509844
[TBL] [Abstract][Full Text] [Related]
24. Lambert-Eaton myasthenic syndrome.
Mareska M; Gutmann L
Semin Neurol; 2004 Jun; 24(2):149-53. PubMed ID: 15257511
[TBL] [Abstract][Full Text] [Related]
25. Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer.
Payne M; Bradbury P; Lang B; Vincent A; Han C; Newsom-Davis J; Talbot D
J Thorac Oncol; 2010 Jan; 5(1):34-8. PubMed ID: 19934775
[TBL] [Abstract][Full Text] [Related]
26. Isolated dysphagia due to paraneoplastic myasthenic syndrome with anti-P/Q-type voltage-gated calcium-channel and anti-acetylcholine receptor antibodies.
Fernandez-Torron R; Arcocha J; López-Picazo JM; Pardo J; Tamura MA; Carretero C; Pastor P
Neuromuscul Disord; 2011 Feb; 21(2):126-8. PubMed ID: 21115345
[TBL] [Abstract][Full Text] [Related]
27. [A case of myasthenia gravis with coexistence of anti-acetylcholine receptor antibodies and anti-P/Q-type VGCC antibodies].
Takeda Y; Noda Y; Seike N; Ishihara H
Rinsho Shinkeigaku; 2024 Apr; 64(4):292-295. PubMed ID: 38508730
[TBL] [Abstract][Full Text] [Related]
28. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.
Sabater L; Titulaer M; Saiz A; Verschuuren J; Güre AO; Graus F
Neurology; 2008 Mar; 70(12):924-8. PubMed ID: 18032743
[TBL] [Abstract][Full Text] [Related]
29. Lambert-Eaton syndrome antibodies target multiple subunits of voltage-gated Ca2+ channels.
Hajela RK; Huntoon KM; Atchison WD
Muscle Nerve; 2015 Feb; 51(2):176-84. PubMed ID: 24862203
[TBL] [Abstract][Full Text] [Related]
30. Monozygous twins with neuromuscular transmission defects at opposite sides of the motor endplate.
Punga AR; Nygren I; Askmark H; Stålberg EV
Acta Neurol Scand; 2009 Mar; 119(3):207-11. PubMed ID: 18684214
[TBL] [Abstract][Full Text] [Related]
31. Calcium channel autoantibodies in myasthenic syndrome and small cell lung cancer.
Pelucchi A; Ciceri E; Clementi F; Marazzini L; Foresi A; Sher E
Am Rev Respir Dis; 1993 May; 147(5):1229-32. PubMed ID: 8387255
[TBL] [Abstract][Full Text] [Related]
32. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome.
Motomura M; Lang B; Johnston I; Palace J; Vincent A; Newsom-Davis J
J Neurol Sci; 1997 Mar; 147(1):35-42. PubMed ID: 9094058
[TBL] [Abstract][Full Text] [Related]
33. Lambert-Eaton myasthenic syndrome as an autoimmune calcium channelopathy.
Takamori M
Biochem Biophys Res Commun; 2004 Oct; 322(4):1347-51. PubMed ID: 15336982
[TBL] [Abstract][Full Text] [Related]
34. Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy.
Hülsbrink R; Hashemolhosseini S
Clin Neurophysiol; 2014 Dec; 125(12):2328-36. PubMed ID: 25065299
[TBL] [Abstract][Full Text] [Related]
35. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival.
Titulaer MJ; Klooster R; Potman M; Sabater L; Graus F; Hegeman IM; Thijssen PE; Wirtz PW; Twijnstra A; Smitt PA; van der Maarel SM; Verschuuren JJ
J Clin Oncol; 2009 Sep; 27(26):4260-7. PubMed ID: 19667272
[TBL] [Abstract][Full Text] [Related]
36. GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome.
Shimizu F; Takeshita Y; Sano Y; Hamamoto Y; Shiraishi H; Sato T; Yoshimura S; Maeda T; Fujikawa S; Nishihara H; Kitanosono H; Tsujino A; Motomura M; Kanda T
Brain; 2019 Aug; 142(8):2253-2264. PubMed ID: 31236596
[TBL] [Abstract][Full Text] [Related]
37. Autoimmune disorders of neuromuscular transmission.
Mahadeva B; Phillips LH; Juel VC
Semin Neurol; 2008 Apr; 28(2):212-27. PubMed ID: 18351523
[TBL] [Abstract][Full Text] [Related]
38. Antibodies to synthetic peptides of the alpha1A subunit of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome.
Takamori M; Iwasa K; Komai K
Neurology; 1997 May; 48(5):1261-5. PubMed ID: 9153453
[TBL] [Abstract][Full Text] [Related]
39. [Autoimmune myasthenia and Lambert-Eaton myasthenic syndrome. Physiopathologic concepts].
Eymard B
Ann Med Interne (Paris); 1989; 140(6):462-6. PubMed ID: 2696402
[TBL] [Abstract][Full Text] [Related]
40. [Immunologic aspects of disorders of neuromuscular transmission. 2. Experimental autoimmune myasthenia gravis and the Lambert-Eaton myasthenic syndrome].
Andreis I; Lovnićki TJ; Beara N; Taradi M
Lijec Vjesn; 1994; 116(5-6):158-61. PubMed ID: 7968205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
